

Amendments to the Claims:

1. (Currently amended) ~~The use~~ Use of an antagonist of ~~placental~~ placenta growth factor for the manufacture of a medicament to treat disorders of bone resorption.

2-8. (Cancelled)

9. (New) The use according to claim 1, wherein said treatment of disorders of bone resorption is a suppression of bone resorption.

10. (New) The use of an antagonist according to claim 1, wherein said antagonist is selected from the group consisting of antibodies binding on placenta growth factor, peptides binding on placenta growth factor, tetrameric peptides binding on placental growth factor or VEGFR-1, small molecules binding on placenta growth factor or VEGFR-1, anti-sense nucleic acids against placenta growth factor or VEGFR-1, interference RNA against placenta growth factor or VEGFR-1 and ribozymes against placenta growth factor or VEGFR-1.

11. (New) The use according to claim 1, wherein said disorder of bone resorption is osteoporosis.

12. (New) The use according to claim 9, wherein said disorder of bone resorption is osteoporosis.

13. (New) The use according to claim 10, wherein said disorder of bone resorption is osteoporosis.

14. (New) A method to identify an individual with excessive bone resorption or a predisposition to acquire a disorder of excessive bone resorption, which comprises identifying a polymorphism of the PlGF promoter and/or elevated levels of PlGF in a sample of said individual.